Bone Marrow Transplant Rejection - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 427
Inquire Before Buying

Global Markets Direct's, ‘Bone Marrow Transplant Rejection - Pipeline Review, H2 2016', provides an overview of the Bone Marrow Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection

  • The report reviews pipeline therapeutics for Bone Marrow Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Bone Marrow Transplant Rejection therapeutics and enlists all their major and minor projects

  • The report assesses Bone Marrow Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplant Rejection

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Bone Marrow Transplant Rejection - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Bone Marrow Transplant Rejection Overview 11
Therapeutics Development 12
Pipeline Products for Bone Marrow Transplant Rejection - Overview 12
Pipeline Products for Bone Marrow Transplant Rejection - Comparative Analysis 13
Bone Marrow Transplant Rejection - Therapeutics under Development by Companies 14
Bone Marrow Transplant Rejection - Therapeutics under Investigation by Universities/Institutes 19
Bone Marrow Transplant Rejection - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Bone Marrow Transplant Rejection - Products under Development by Companies 25
Bone Marrow Transplant Rejection - Products under Investigation by Universities/Institutes 31
Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development 33
AbbVie Inc 33
AbGenomics International, Inc. 34
Actelion Ltd 35
Alexion Pharmaceuticals Inc 36
Amunix Operating Inc. 37
Apceth GmbH & Co. KG 38
arGEN-X BV 39
Athersys, Inc. 40
Bellicum Pharmaceuticals, Inc. 41
Bio-Cancer Treatment International Limited 42
Biogen Inc 43
Boryung Pharmaceutical Co., Ltd. 44
Bristol-Myers Squibb Company 45
Cantex Pharmaceuticals, Inc. 46
Capricor Therapeutics, Inc. 47
Cell Source, Inc. 48
Cell2B S.A. 49
CellECT Bio, Inc. 50
Cleveland BioLabs, Inc. 51
Compugen Ltd. 52
Cynata Therapeutics Limited 53
Cytodyn Inc. 54
Dompe Farmaceutici S.p.A. 55
Dr. Falk Pharma GmbH 56
Escape Therapeutics, Inc. 57
F. Hoffmann-La Roche Ltd. 58
Fate Therapeutics, Inc. 59
Generon (Shanghai) Corporation Ltd. 60
Gilead Sciences, Inc. 61
GlaxoSmithKline Plc 62
Idera Pharmaceuticals, Inc. 63
ImmuNext, Inc. 64
Immunomedics, Inc. 65
Incyte Corporation 66
Kadmon Corporation, LLC 67
Kamada Ltd. 68
Kiadis Pharma N.V. 69
Kymab Limited 70
Kyorin Pharmaceutical Co., Ltd. 71
MacroGenics, Inc. 72
Mallinckrodt Plc 73
Medsenic 74
Mesoblast Limited 75
Millennium Pharmaceuticals Inc 76
Neopharm Ltd. 77
Nohla Therapeutics Inc. 78
Novartis AG 79
OncoImmune, Inc. 80
OSE Immunotherapeutics 81
Pharmicell Co., Ltd. 82
Pluristem Therapeutics Inc. 83
REGiMMUNE Corporation 84
Rigel Pharmaceuticals, Inc. 85
Sarepta Therapeutics, Inc. 86
Seattle Genetics, Inc. 87
Seres Therapeutics, Inc. 88
Sigmoid Pharma Limited 89
Spherium Biomed S.L. 90
Taiga Biotechnologies, Inc. 91
Takeda Pharmaceutical Company Limited 92
Targazyme, Inc. 93
Therapix Biosciences Ltd 94
Tobira Therapeutics, Inc. 95
Vault Pharma Inc. 96
Xenikos B.V. 97
ZIOPHARM Oncology, Inc. 98
Bone Marrow Transplant Rejection - Therapeutics Assessment 99
Assessment by Monotherapy Products 99
Assessment by Combination Products 100
Assessment by Target 101
Assessment by Mechanism of Action 105
Assessment by Route of Administration 109
Assessment by Molecule Type 111
Drug Profiles 113
abatacept - Drug Profile 113
AbGn-168H - Drug Profile 118
AGS-499 - Drug Profile 120
aldesleukin - Drug Profile 121
Alecmestencel-L - Drug Profile 123
alpha-1 proteinase inhibitor (human) - Drug Profile 124
ALXN-1007 - Drug Profile 129
AMX-342 - Drug Profile 130
anti-thymocyte globulin (rabbit) - Drug Profile 131
Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile 133
Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 134
ARGX-115 - Drug Profile 135
arsenic trioxide - Drug Profile 136
ATIR-101 - Drug Profile 137
BCT-200 - Drug Profile 141
begelomab - Drug Profile 142
Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile 143
Biologics for Graft Versus Host Disease - Drug Profile 144
bortezomib - Drug Profile 145
BPX-501 - Drug Profile 153
BR-05001 - Drug Profile 157
brentuximab vedotin - Drug Profile 158
budesonide - Drug Profile 182
cannabidiol - Drug Profile 185
CAP-2003 - Drug Profile 186
CBLB-612 - Drug Profile 187
CD-24Fc - Drug Profile 189
Cell Therapy for Graft Versus Host Disease - Drug Profile 190
Cell Therapy for Graft-Versus Host Disease - Drug Profile 191
Cellgram for Graft Versus Host Disease - Drug Profile 192
Cellular Immunotherapy for Acute Graft Versus Host Disease - Drug Profile 193
Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile 194
Cellular Immunotherapy for Bone Marrow Transplantation - Drug Profile 196
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 197
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 198
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 199
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 200
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 201
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 202
Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 203
Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile 204
cenicriviroc mesylate - Drug Profile 205
CGEN-15001 - Drug Profile 212
CRCBT-080004 - Drug Profile 215
CX-01 - Drug Profile 216
cyclosporine CR + cyclosporine IR - Drug Profile 218
CYP-001 - Drug Profile 219
entospletinib - Drug Profile 220
F-652 - Drug Profile 222
FR-104 - Drug Profile 223
Ha-7 - Drug Profile 226
ibrutinib - Drug Profile 227
ImmuneSafe - Drug Profile 252
ImmuStem - Drug Profile 253
IMO-8400 - Drug Profile 254
IT-603 - Drug Profile 260
IT-901 - Drug Profile 261
itacitinib adipate - Drug Profile 262
KD-025 - Drug Profile 265
KRP-203 - Drug Profile 269
KY-1005 - Drug Profile 271
MAX-16H5 - Drug Profile 272
MesoStem - Drug Profile 273
methoxsalen - Drug Profile 274
MGD-010 - Drug Profile 276
milatuzumab - Drug Profile 278
Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases - Drug Profile 281
MPC-CBE - Drug Profile 283
natalizumab - Drug Profile 285
obinutuzumab - Drug Profile 290
OCU-300 - Drug Profile 297
Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile 298
panobinostat - Drug Profile 299
PF-05285401 - Drug Profile 307
PLXR-18 - Drug Profile 318
ponesimod - Drug Profile 325
Preimplantation Factor - Drug Profile 328
PRO-140 - Drug Profile 329
ProTmune - Drug Profile 337
R-348 - Drug Profile 339
Recombinant Protein for Graft Versus Host Disease and Autoimmune Disorders - Drug Profile 341
Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile 342
Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile 343
remestemcel-L - Drug Profile 344
reparixin - Drug Profile 349
RGI-2001 - Drug Profile 352
RO-2959 - Drug Profile 354
rovalpituzumab tesirine - Drug Profile 355
ruxolitinib phosphate - Drug Profile 357
S-Graft - Drug Profile 370
SER-155 - Drug Profile 371
Small Molecule for Autoimmune Disorders, Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis - Drug Profile 372
Small Molecule to Inhibit Protein Kinase C Theta for Immunological Disorders and Multiple Sclerosis - Drug Profile 373
Small Molecules to Inhibit Perforin for Bone Marrow Transplantation - Drug Profile 374
Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile 375
Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders - Drug Profile 376
sonidegib phosphate - Drug Profile 377
SP-12008 - Drug Profile 382
SYGN-305 - Drug Profile 383
Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile 384
T-Guard - Drug Profile 385
TBX-1400 - Drug Profile 387
TM-5509 - Drug Profile 388
TZ-101 - Drug Profile 389
vedolizumab - Drug Profile 392
VPI-101 - Drug Profile 397
ZL-1101 - Drug Profile 398
Bone Marrow Transplant Rejection - Dormant Projects 399
Bone Marrow Transplant Rejection - Discontinued Products 405
Bone Marrow Transplant Rejection - Product Development Milestones 406
Featured News & Press Releases 406
Appendix 418
Methodology 418
Coverage 418
Secondary Research 418
Primary Research 418
Expert Panel Validation 418
Contact Us 418
Disclaimer 419

List of Tables

Number of Products under Development for Bone Marrow Transplant Rejection, H2 2016 20
Number of Products under Development for Bone Marrow Transplant Rejection - Comparative Analysis, H2 2016 21
Number of Products under Development by Companies, H2 2016 22
Number of Products under Development by Companies, H2 2016 (Contd..1) 23
Number of Products under Development by Companies, H2 2016 (Contd..2) 24
Number of Products under Development by Companies, H2 2016 (Contd..3) 25
Number of Products under Development by Companies, H2 2016 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H2 2016 28
Comparative Analysis by Late Stage Development, H2 2016 29
Comparative Analysis by Clinical Stage Development, H2 2016 30
Comparative Analysis by Early Stage Development, H2 2016 31
Comparative Analysis by Unknown Stage Development, H2 2016 32
Products under Development by Companies, H2 2016 33
Products under Development by Companies, H2 2016 (Contd..1) 34
Products under Development by Companies, H2 2016 (Contd..2) 35
Products under Development by Companies, H2 2016 (Contd..3) 36
Products under Development by Companies, H2 2016 (Contd..4) 37
Products under Development by Companies, H2 2016 (Contd..5) 38
Products under Investigation by Universities/Institutes, H2 2016 39
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 40
Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc, H2 2016 41
Bone Marrow Transplant Rejection - Pipeline by AbGenomics International, Inc., H2 2016 42
Bone Marrow Transplant Rejection - Pipeline by Actelion Ltd, H2 2016 43
Bone Marrow Transplant Rejection - Pipeline by Alexion Pharmaceuticals Inc, H2 2016 44
Bone Marrow Transplant Rejection - Pipeline by Amunix Operating Inc. , H2 2016 45
Bone Marrow Transplant Rejection - Pipeline by Apceth GmbH & Co. KG, H2 2016 46
Bone Marrow Transplant Rejection - Pipeline by arGEN-X BV, H2 2016 47
Bone Marrow Transplant Rejection - Pipeline by Athersys, Inc., H2 2016 48
Bone Marrow Transplant Rejection - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 49
Bone Marrow Transplant Rejection - Pipeline by Bio-Cancer Treatment International Limited, H2 2016 50
Bone Marrow Transplant Rejection - Pipeline by Biogen Inc, H2 2016 51
Bone Marrow Transplant Rejection - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2016 52
Bone Marrow Transplant Rejection - Pipeline by Bristol-Myers Squibb Company, H2 2016 53
Bone Marrow Transplant Rejection - Pipeline by Cantex Pharmaceuticals, Inc., H2 2016 54
Bone Marrow Transplant Rejection - Pipeline by Capricor Therapeutics, Inc., H2 2016 55
Bone Marrow Transplant Rejection - Pipeline by Cell Source, Inc., H2 2016 56
Bone Marrow Transplant Rejection - Pipeline by Cell2B S.A. , H2 2016 57
Bone Marrow Transplant Rejection - Pipeline by CellECT Bio, Inc., H2 2016 58
Bone Marrow Transplant Rejection - Pipeline by Cleveland BioLabs, Inc., H2 2016 59
Bone Marrow Transplant Rejection - Pipeline by Compugen Ltd., H2 2016 60
Bone Marrow Transplant Rejection - Pipeline by Cynata Therapeutics Limited, H2 2016 61
Bone Marrow Transplant Rejection - Pipeline by Cytodyn Inc., H2 2016 62
Bone Marrow Transplant Rejection - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 63
Bone Marrow Transplant Rejection - Pipeline by Dr. Falk Pharma GmbH, H2 2016 64
Bone Marrow Transplant Rejection - Pipeline by Escape Therapeutics, Inc., H2 2016 65
Bone Marrow Transplant Rejection - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 66
Bone Marrow Transplant Rejection - Pipeline by Fate Therapeutics, Inc., H2 2016 67
Bone Marrow Transplant Rejection - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 68
Bone Marrow Transplant Rejection - Pipeline by Gilead Sciences, Inc., H2 2016 69
Bone Marrow Transplant Rejection - Pipeline by GlaxoSmithKline Plc, H2 2016 70
Bone Marrow Transplant Rejection - Pipeline by Idera Pharmaceuticals, Inc., H2 2016 71
Bone Marrow Transplant Rejection - Pipeline by ImmuNext, Inc., H2 2016 72
Bone Marrow Transplant Rejection - Pipeline by Immunomedics, Inc., H2 2016 73
Bone Marrow Transplant Rejection - Pipeline by Incyte Corporation, H2 2016 74
Bone Marrow Transplant Rejection - Pipeline by Kadmon Corporation, LLC, H2 2016 75
Bone Marrow Transplant Rejection - Pipeline by Kamada Ltd., H2 2016 76
Bone Marrow Transplant Rejection - Pipeline by Kiadis Pharma N.V., H2 2016 77
Bone Marrow Transplant Rejection - Pipeline by Kymab Limited, H2 2016 78
Bone Marrow Transplant Rejection - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 79
Bone Marrow Transplant Rejection - Pipeline by MacroGenics, Inc., H2 2016 80
Bone Marrow Transplant Rejection - Pipeline by Mallinckrodt Plc, H2 2016 81
Bone Marrow Transplant Rejection - Pipeline by Medsenic, H2 2016 82
Bone Marrow Transplant Rejection - Pipeline by Mesoblast Limited, H2 2016 83
Bone Marrow Transplant Rejection - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 84
Bone Marrow Transplant Rejection - Pipeline by Neopharm Ltd., H2 2016 85
Bone Marrow Transplant Rejection - Pipeline by Nohla Therapeutics Inc., H2 2016 86
Bone Marrow Transplant Rejection - Pipeline by Novartis AG, H2 2016 87
Bone Marrow Transplant Rejection - Pipeline by OncoImmune, Inc., H2 2016 88
Bone Marrow Transplant Rejection - Pipeline by OSE Immunotherapeutics, H2 2016 89
Bone Marrow Transplant Rejection - Pipeline by Pharmicell Co., Ltd., H2 2016 90
Bone Marrow Transplant Rejection - Pipeline by Pluristem Therapeutics Inc., H2 2016 91
Bone Marrow Transplant Rejection - Pipeline by REGiMMUNE Corporation, H2 2016 92
Bone Marrow Transplant Rejection - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 93
Bone Marrow Transplant Rejection - Pipeline by Sarepta Therapeutics, Inc., H2 2016 94
Bone Marrow Transplant Rejection - Pipeline by Seattle Genetics, Inc., H2 2016 95
Bone Marrow Transplant Rejection - Pipeline by Seres Therapeutics, Inc., H2 2016 96
Bone Marrow Transplant Rejection - Pipeline by Sigmoid Pharma Limited, H2 2016 97
Bone Marrow Transplant Rejection - Pipeline by Spherium Biomed S.L., H2 2016 98
Bone Marrow Transplant Rejection - Pipeline by Taiga Biotechnologies, Inc., H2 2016 99
Bone Marrow Transplant Rejection - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 100
Bone Marrow Transplant Rejection - Pipeline by Targazyme, Inc., H2 2016 101
Bone Marrow Transplant Rejection - Pipeline by Therapix Biosciences Ltd, H2 2016 102
Bone Marrow Transplant Rejection - Pipeline by Tobira Therapeutics, Inc., H2 2016 103
Bone Marrow Transplant Rejection - Pipeline by Vault Pharma Inc., H2 2016 104
Bone Marrow Transplant Rejection - Pipeline by Xenikos B.V., H2 2016 105
Bone Marrow Transplant Rejection - Pipeline by ZIOPHARM Oncology, Inc., H2 2016 106
Assessment by Monotherapy Products, H2 2016 107
Assessment by Combination Products, H2 2016 108
Number of Products by Stage and Target, H2 2016 110
Number of Products by Stage and Mechanism of Action, H2 2016 114
Number of Products by Stage and Route of Administration, H2 2016 118
Number of Products by Stage and Molecule Type, H2 2016 120
Bone Marrow Transplant Rejection - Dormant Projects, H2 2016 406
Bone Marrow Transplant Rejection - Dormant Projects (Contd..1), H2 2016 407
Bone Marrow Transplant Rejection - Dormant Projects (Contd..2), H2 2016 408
Bone Marrow Transplant Rejection - Dormant Projects (Contd..3), H2 2016 409
Bone Marrow Transplant Rejection - Dormant Projects (Contd..4), H2 2016 410
Bone Marrow Transplant Rejection - Dormant Projects (Contd..5), H2 2016 411
Bone Marrow Transplant Rejection - Discontinued Products, H2 2016 412

List of Figures

Number of Products under Development for Bone Marrow Transplant Rejection, H2 2016 20
Number of Products under Development for Bone Marrow Transplant Rejection - Comparative Analysis, H2 2016 21
Number of Products under Development by Companies, H2 2016 22
Number of Products under Investigation by Universities/Institutes, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 30
Comparative Analysis by Early Stage Products, H2 2016 31
Assessment by Monotherapy Products, H2 2016 107
Number of Products by Top 10 Targets, H2 2016 109
Number of Products by Stage and Top 10 Targets, H2 2016 109
Number of Products by Top 10 Mechanism of Actions, H2 2016 113
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 113
Number of Products by Top 10 Routes of Administration, H2 2016 117
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 117
Number of Products by Top 10 Molecule Types, H2 2016 119
Number of Products by Stage and Top 10 Molecule Types, H2 2016 119
  • 2017-2022 Global Top Countries Pertussis Vaccine Market Report
    Published: 27-Mar-2017        Price: US 4960 Onwards        Pages: 127
    This report studies Pertussis Vaccine in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, Middle East and Africa, focuses on the top Manufacturers in each country, covering - Sanofi Pasteur - GSK - Mitsubishi Tanabe Pharma - Astellas Pharma - Minhai Biotechnology - Wuhan Institute of - Biological Products - Changchun Changshe......
  • 2017-2022 China Pertussis Vaccine Market Report (Status and Outlook)
    Published: 27-Mar-2017        Price: US 3360 Onwards        Pages: 114
    The Pertussis Vaccine market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In China market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Sanofi Pasteur - GSK - Mitsubishi Tanabe Pharma - Astellas Pharma - Minhai Biotechnology - Wuhan Institute of - Bio......
  • Global Procalcitonin (CAS 56645-65-9) Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 24-Mar-2017        Price: US 3480 Onwards        Pages: 116
    Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. Scope of the Report: This report focuses on the Procalcitonin (CAS 56645-65-9) in Global m......
  • Global Steroid-Corticosteroids Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 23-Mar-2017        Price: US 3480 Onwards        Pages: 124
    Steroid-Corticosteroids are a class of steroid hormones that are produced in the adrenal cortex of vertebrates, as well as the synthetic analogues of these hormones. Scope of the Report: This report focuses on the Steroid-Corticosteroids in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Market Segment b......
  • Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022) - By Region (N. America, Europe, APAC, RoW); By Country (US, Canada, UK, Germany, France, Japan, China, Singapore, India, Brazil, South Africa)
    Published: 22-Mar-2017        Price: US 1800 Onwards        Pages: 154
    Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Antibody Drug Conjugates Market on the basis of Analysis By Drug (Adcetris, Kadcyla), Pipeline Analysis (Developer, Phase, Indication, Status, Cytotoxic Payload, Linker, Target), By Region (North America, Europe, APAC and ROW) and By Country (U.S., ......
  • 2017-2022 Japan Pertussis Vaccine Market Report (Status and Outlook)
    Published: 22-Mar-2017        Price: US 3360 Onwards        Pages: 114
    "This report will be delivered in 2-3 business days after the order is placed." The Pertussis Vaccine market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Japan market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Sanofi Pasteur - GSK - Mitsubis......
  • 2017-2022 India Pertussis Vaccine Market Report (Status and Outlook)
    Published: 22-Mar-2017        Price: US 3360 Onwards        Pages: 114
    "This report will be delivered in 2-3 business days after the order is placed." The Pertussis Vaccine market size will be XX million (USD) in 2022 in India, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In India market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Sanofi Pasteur - GSK - Mitsubis......
  • 2017-2022 Germany Pertussis Vaccine Market Report (Status and Outlook)
    Published: 22-Mar-2017        Price: US 3360 Onwards        Pages: 116
    "This report will be delivered in 2-3 business days after the order is placed." The Pertussis Vaccine market size will be XX million (USD) in 2022 in Germany, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Germany market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Sanofi Pasteur - GSK - Mits......
  • Nordics Seasonal Influenza Vaccine Market Forecast in (Denmark, Finland, Iceland, Norway & Sweden) By (Child & Adult) Vaccination
    Published: 21-Mar-2017        Price: US 1250 Onwards        Pages: 90
    Nordics Seasonal Influenza Vaccine Market Forecast in (Denmark, Finland, Iceland, Norway & Sweden) By (Child & Adult) Vaccination report published by Renub Research. According to this report, Sweden is having the highest seasonal influenza vaccine market share. In terms of children vaccination, Sweden & Denmark hold nearly 70 percent market share in 2016 whereas, in adult vaccination segments, these two will share more than 60 percent market share by 2022. This report prov......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs